CJC-1295 vs Adipotide
Side-by-Side Comparison
| Attribute | Cjc 1295 | Adipotide |
|---|---|---|
| Category | Growth Hormone Secretagogue | Experimental Fat Loss |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | Adipotide has a dual-domain design. The homing peptide CKGGRAKDC binds to prohibitin on the surface of endothelial cells in white adipose tissue vasculature (prohibitin is overexpressed on fat tissue... |
| Evidence Rating | D — Preclinical | D — Animal/Preclinical Only |
| Clinical Status | Research-only / Not approved for human use | Clinical development discontinued. Preclinical only (primate proof-of-concept). No human trials conducted. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | CRITICAL: Reversible kidney toxicity observed in all primate studies; Mechanism: prohibitin expression in kidney proximal tubule cells causes off-target damage |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 250-1000 mcg per injection (EXPERIMENTAL — NO ESTABLISHED HUMAN DOSE) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~3,200 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~2-4 hours (estimated) |
Overview
CJC-1295 and Adipotide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
Adipotide — Mechanism & Evidence
Adipotide (FTPP) is a chimeric peptidomimetic (MW ~3,200 g/mol) composed of a prohibitin-targeting domain (CKGGRAKDC) linked to a proapoptotic domain D(KLAKLAK)2. It selectively targets and destroys blood vessels supplying white adipose tissue, causing rapid fat loss through vascular disruption and subsequent adipocyte death. In rhesus monkeys, it produced 11% weight loss in 4 weeks. Clinical development was discontinued due to reversible kidney toxicity observed in primate studies.
Key claims: Rapid and significant fat loss; Selectively targets fat tissue vasculature; Improves metabolic parameters.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
Adipotide is also researched for: no additional unique applications.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Adipotide: CRITICAL: Reversible kidney toxicity observed in all primate studies Mechanism: prohibitin expression in kidney proximal tubule cells causes off-target damage Elevated BUN and creatinine during treatment; reversed after discontinuation
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.